CD4 binding determinant mimicry for HIV vaccine design

Area of Science:

• Immunology
• Virology
• Vaccine Development

Background:

• HIV-1 envelope protein gp120's hypermutable epitopes hinder vaccine development.
• The conserved CD4 binding domain (CD4BD) is a potential vaccine target but faces challenges due to gp120's flexibility and immune evasion.
• Mimicking discontinuous outer CD4BD epitopes is difficult; the linear CD4BD(core) epitope has superantigenic properties.

Purpose of the Study:

• To explore a novel strategy for inducing neutralizing antibodies against the HIV-1 gp120 CD4BD.
• To investigate the potential of electrophilic gp120 (E-gp120) analogs for covalent binding to B cell receptors (BCRs).
• To overcome limitations of flexible peptides and B cell checkpoints in vaccine design.

Main Methods:

• Development of an electrophilic gp120 (E-gp120) analog designed for covalent BCR interaction.
• Hypothesizing that covalent binding converts superantigen-BCR interactions into stimulatory signals.
• Utilizing flexible synthetic peptides to detect pre-existing antibodies and assessing induced antibody responses.

Main Results:

• E-gp120 analogs induce synthesis of neutralizing antibodies against the CD4BD(core).
• Covalent binding is hypothesized to provide a strong stimulatory signal, potentially enhanced by a second epitope.
• Flexible peptides can detect existing antibodies but may induce non-neutralizing responses.

Conclusions:

• Covalent modification of BCRs by E-gp120 is a promising approach for inducing neutralizing antibodies against conserved HIV epitopes.
• A rigid immunogen mimicking native epitope conformation is necessary to bypass B cell checkpoints and achieve effective vaccination.
• This strategy offers a potential pathway to a broadly protective HIV vaccine by targeting the vulnerable CD4BD.